[6-K] Smith & Nephew plc Current Report (Foreign Issuer)
Smith & Nephew announced the appointment of Dr Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective 1 September 2025. Dr Kong is managing partner and co-founder of HealthQuest Capital and holds non-executive roles including lead independent director of LabCorp and directorships at Xeris Biopharma, Lunit and IKS Health. The company notes his prior roles at Sofinnova Investments and several medtech and biopharma boards. Smith & Nephew describes itself as a global medical technology group with about 17,000 employees, operations in around 100 countries and annual sales of $5.8 billion in 2024. The filing states no UK Listing Rule disclosure obligations arise for this appointment.
Smith & Nephew ha annunciato la nomina del dott. Garheng Kong a direttore non esecutivo indipendente e membro del Comitato di Revisione, con effetto dal 1° settembre 2025. Il dott. Kong è managing partner e cofondatore di HealthQuest Capital e ricopre incarichi non esecutivi, tra cui quello di lead independent director di LabCorp e di amministratore presso Xeris Biopharma, Lunit e IKS Health. La società evidenzia i suoi precedenti ruoli in Sofinnova Investments e in vari consigli di amministrazione di aziende medtech e biopharma. Smith & Nephew si definisce un gruppo globale di tecnologia medica con circa 17.000 dipendenti, attività in circa 100 paesi e vendite annue per 5,8 miliardi di dollari nel 2024. Il comunicato specifica che per questa nomina non sussistono obblighi di comunicazione ai sensi delle UK Listing Rules.
Smith & Nephew anunció el nombramiento del Dr. Garheng Kong como director no ejecutivo independiente y miembro del Comité de Auditoría, con efecto desde el 1 de septiembre de 2025. El Dr. Kong es socio director y cofundador de HealthQuest Capital y desempeña cargos no ejecutivos, entre ellos el de lead independent director en LabCorp y consejos de administración en Xeris Biopharma, Lunit e IKS Health. La compañía destaca sus anteriores puestos en Sofinnova Investments y en diversos consejos de empresas medtech y biopharma. Smith & Nephew se describe como un grupo global de tecnología médica con alrededor de 17.000 empleados, presencia en cerca de 100 países y ventas anuales de 5.800 millones de dólares en 2024. La nota indica que esta designación no genera obligaciones de divulgación bajo las UK Listing Rules.
Smith & Nephew는 2025년 9월 1일부로 Dr. Garheng Kong을 독립 비상임 이사 겸 감사위원회 위원으로 선임했다고 발표했습니다. Kong 박사는 HealthQuest Capital의 매니징 파트너이자 공동 설립자이며, LabCorp의 수석 독립이사(lead independent director)를 포함한 비상임직과 Xeris Biopharma, Lunit, IKS Health의 이사직을 맡고 있습니다. 회사는 그가 Sofinnova Investments와 여러 메드테크·바이오파마 이사회에서 활동한 경력을 갖고 있다고 전했습니다. Smith & Nephew는 약 17,000명의 직원과 약 100개국에서의 사업, 2024년 연간 매출 58억 달러를 보유한 글로벌 의료기술 그룹이라고 설명합니다. 공시문은 이번 선임에 관해 영국 상장 규정(UK Listing Rules)에 따른 별도 공시 의무는 발생하지 않는다고 명시했습니다.
Smith & Nephew a annoncé la nomination du Dr Garheng Kong en tant qu'administrateur non exécutif indépendant et membre du comité d'audit, effective au 1er septembre 2025. Le Dr Kong est managing partner et cofondateur de HealthQuest Capital et occupe des postes non exécutifs, notamment celui de lead independent director chez LabCorp, ainsi que des sièges au conseil d'administration de Xeris Biopharma, Lunit et IKS Health. La société souligne ses précédents rôles chez Sofinnova Investments et dans plusieurs conseils d'administration de sociétés medtech et biopharma. Smith & Nephew se décrit comme un groupe mondial de technologie médicale d'environ 17 000 employés, présent dans près de 100 pays et ayant réalisé 5,8 milliards de dollars de ventes en 2024. Le dépôt précise qu'aucune obligation de divulgation au titre des UK Listing Rules ne résulte de cette nomination.
Smith & Nephew hat die Ernennung von Dr. Garheng Kong zum unabhängigen nicht-exekutiven Direktor und Mitglied des Prüfungsausschusses mit Wirkung zum 1. September 2025 bekannt gegeben. Dr. Kong ist Managing Partner und Mitgründer von HealthQuest Capital und bekleidet mehrere nicht-exekutive Positionen, darunter Lead Independent Director bei LabCorp sowie Aufsichtsratsposten bei Xeris Biopharma, Lunit und IKS Health. Das Unternehmen weist auf seine früheren Tätigkeiten bei Sofinnova Investments und in verschiedenen MedTech- und Biopharma-Aufsichtsräten hin. Smith & Nephew beschreibt sich als globales Medizintechnikunternehmen mit rund 17.000 Mitarbeitern, Aktivitäten in etwa 100 Ländern und einem Jahresumsatz von 5,8 Mrd. USD im Jahr 2024. Die Meldung stellt klar, dass durch diese Ernennung keine Offenlegungspflichten nach den UK Listing Rules entstehen.
- None.
- None.
Insights
TL;DR: Routine independent director appointment strengthens board expertise in medtech and investment, with no required UKLR disclosures.
Dr Garheng Kong brings combined clinical, technical and investment experience from leadership roles at HealthQuest Capital and several public biotech and medtech boards. His appointment to the Audit Committee adds governance capacity given his industry and investor background. The filing explicitly states that paragraphs (1)–(6) of UKLR 6.4.8R do not trigger disclosure obligations, indicating no reported conflicts or material interests tied to the appointment. This is a non-transactional, governance-focused update rather than a material operational or financial development.
TL;DR: Adds sector-specific experience that could support product and commercial strategy oversight; appointment is informational, not financial.
Dr Kong's background across venture investing and board roles at diagnostics and biopharma firms suggests relevant oversight capability for Smith & Nephew's technology and portfolio development. His investor perspective may assist in assessing R&D priorities and potential strategic transactions. The announcement contains no operational metrics or transaction terms and does not indicate immediate impact on revenue, margins or balance sheet items.
Smith & Nephew ha annunciato la nomina del dott. Garheng Kong a direttore non esecutivo indipendente e membro del Comitato di Revisione, con effetto dal 1° settembre 2025. Il dott. Kong è managing partner e cofondatore di HealthQuest Capital e ricopre incarichi non esecutivi, tra cui quello di lead independent director di LabCorp e di amministratore presso Xeris Biopharma, Lunit e IKS Health. La società evidenzia i suoi precedenti ruoli in Sofinnova Investments e in vari consigli di amministrazione di aziende medtech e biopharma. Smith & Nephew si definisce un gruppo globale di tecnologia medica con circa 17.000 dipendenti, attività in circa 100 paesi e vendite annue per 5,8 miliardi di dollari nel 2024. Il comunicato specifica che per questa nomina non sussistono obblighi di comunicazione ai sensi delle UK Listing Rules.
Smith & Nephew anunció el nombramiento del Dr. Garheng Kong como director no ejecutivo independiente y miembro del Comité de Auditoría, con efecto desde el 1 de septiembre de 2025. El Dr. Kong es socio director y cofundador de HealthQuest Capital y desempeña cargos no ejecutivos, entre ellos el de lead independent director en LabCorp y consejos de administración en Xeris Biopharma, Lunit e IKS Health. La compañía destaca sus anteriores puestos en Sofinnova Investments y en diversos consejos de empresas medtech y biopharma. Smith & Nephew se describe como un grupo global de tecnología médica con alrededor de 17.000 empleados, presencia en cerca de 100 países y ventas anuales de 5.800 millones de dólares en 2024. La nota indica que esta designación no genera obligaciones de divulgación bajo las UK Listing Rules.
Smith & Nephew는 2025년 9월 1일부로 Dr. Garheng Kong을 독립 비상임 이사 겸 감사위원회 위원으로 선임했다고 발표했습니다. Kong 박사는 HealthQuest Capital의 매니징 파트너이자 공동 설립자이며, LabCorp의 수석 독립이사(lead independent director)를 포함한 비상임직과 Xeris Biopharma, Lunit, IKS Health의 이사직을 맡고 있습니다. 회사는 그가 Sofinnova Investments와 여러 메드테크·바이오파마 이사회에서 활동한 경력을 갖고 있다고 전했습니다. Smith & Nephew는 약 17,000명의 직원과 약 100개국에서의 사업, 2024년 연간 매출 58억 달러를 보유한 글로벌 의료기술 그룹이라고 설명합니다. 공시문은 이번 선임에 관해 영국 상장 규정(UK Listing Rules)에 따른 별도 공시 의무는 발생하지 않는다고 명시했습니다.
Smith & Nephew a annoncé la nomination du Dr Garheng Kong en tant qu'administrateur non exécutif indépendant et membre du comité d'audit, effective au 1er septembre 2025. Le Dr Kong est managing partner et cofondateur de HealthQuest Capital et occupe des postes non exécutifs, notamment celui de lead independent director chez LabCorp, ainsi que des sièges au conseil d'administration de Xeris Biopharma, Lunit et IKS Health. La société souligne ses précédents rôles chez Sofinnova Investments et dans plusieurs conseils d'administration de sociétés medtech et biopharma. Smith & Nephew se décrit comme un groupe mondial de technologie médicale d'environ 17 000 employés, présent dans près de 100 pays et ayant réalisé 5,8 milliards de dollars de ventes en 2024. Le dépôt précise qu'aucune obligation de divulgation au titre des UK Listing Rules ne résulte de cette nomination.
Smith & Nephew hat die Ernennung von Dr. Garheng Kong zum unabhängigen nicht-exekutiven Direktor und Mitglied des Prüfungsausschusses mit Wirkung zum 1. September 2025 bekannt gegeben. Dr. Kong ist Managing Partner und Mitgründer von HealthQuest Capital und bekleidet mehrere nicht-exekutive Positionen, darunter Lead Independent Director bei LabCorp sowie Aufsichtsratsposten bei Xeris Biopharma, Lunit und IKS Health. Das Unternehmen weist auf seine früheren Tätigkeiten bei Sofinnova Investments und in verschiedenen MedTech- und Biopharma-Aufsichtsräten hin. Smith & Nephew beschreibt sich als globales Medizintechnikunternehmen mit rund 17.000 Mitarbeitern, Aktivitäten in etwa 100 Ländern und einem Jahresumsatz von 5,8 Mrd. USD im Jahr 2024. Die Meldung stellt klar, dass durch diese Ernennung keine Offenlegungspflichten nach den UK Listing Rules entstehen.
FAQ
Who has Smith & Nephew appointed to its board in September 2025 (SNN)?
What is Dr Garheng Kong's background?
Does this appointment trigger any UK Listing Rule disclosures?
What company metrics are provided in the filing for Smith & Nephew?
Will this appointment materially affect Smith & Nephew's financials?
